Trial Profile

A Phase 1 Study of TRU-016 in Combination With Rituximab and Bendamustine in Subjects With Relapsed Indolent Lymphoma

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 08 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Otlertuzumab (Primary) ; Bendamustine; Rituximab
Indications B-cell lymphoma; Chronic lymphocytic leukaemia; Follicular lymphoma; Non-Hodgkin's lymphoma
Focus Pharmacogenomic; Therapeutic Use
Sponsors Emergent BioSolutions

Most Recent Events

01 Aug 2013 The phase II portion of this trial was not conducted, according to the ClinicalTrials.gov record.
13 Nov 2012 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
05 Nov 2012 Twelve patients were enrolled and treated in the phase Ib component of the trial according to an Emergent BioSolutions media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com